Kidney care firm Strive Health scored a whopping $166 million in Collection C funding led by NEA alongside strategic investor CVS Well being Ventures.
Current traders CapitalG (Alphabet), City Corridor Ventures, Redpoint, Echo Ventures and Ascension Ventures additionally participated within the spherical.
WHAT IT DOES
The Denver-based firm presents a value-based care platform that integrates persistent kidney illness and end-stage renal illness affected person knowledge from varied methods into one platform. The know-how was designed to establish illness development and make predictions a few affected person’s situation.
The corporate additionally presents sufferers help by way of kidney transplants and dialysis, with sufferers accessing dialysis by way of conventional strategies or house hemodialysis by way of Try’s collaboration with Outset Medical.
The funds will probably be used to develop partnerships with Medicare, business and Medicare Benefit payors, physicians and well being methods.
“With the brand new funding, we’ll proceed to develop in new markets and scale in our present markets as these turn out to be extra dense. We’ll do that by refining our care mannequin, enhancing our know-how supply and scaling the enterprise throughout the U.S.,” Chris Riopelle, CEO and cofounder of Try, informed MobiHealthNews in an electronic mail. “For the following section of firm progress, we’ll additionally proceed to draw and retain our nice workers as that is the constructing block of what makes the corporate profitable. We all know we are able to solely handle different folks nicely once we handle our personal folks, or what we name Strivers, first.”
In 2021, Try Well being garnered $140 million in Series B funding led by Alphabet’s progress fund CapitalG, which was anticipated to provide the corporate “distinctive entry” to Google and Alphabet belongings.
One other firm within the kidney care area is tech-backed persistent kidney illness and end-stage renal illness administration firm Monogram Health. Monogram scored a whopping $375 million in growth funding in January, simply two years after it closed a $160 million Series B funding round,